NCT02887885已完成不适用
Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Mean change in vaginal maturation index (VMI)
研究概览
简要总结
Sustainability of vaginal ultra-low dose estrogen therapy in postmenopausal women
详细描述
Within this trial 50 postmenopausal women receive a vaginal estrogen therapy as treatment for symptomatic vaginal atrophy. The sustainability of vaginal estrogen therapy after the end of therapy has not yet been investigated.
All participants will be asked to come for the following 7 visits.
- Visit 1: Standard Gynecological examination; Inclusion and exclusion criteria check
- Visit 2: Handing out of Gynoflor (estrogen) for a 6 weeks treatment.
- Visit 3 (Study Start): After using the vaginal estrogen for 6 weeks, a vaginal swap will be done to measure the vaginal maturation index (VMI). The participants will also receive a questionnaire to define some subjective parameters. The parameters measured at visit 1 will count as reference. The estrogen therapy will now be sustained.
- Visit 4-6: Measuring of the VMI and handing out the questionnaires to define subjective parameters.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal women (last menstrual period more than 12 months ago or having undergone bilateral ovariectomy)
- •Age ≥ 18 years
- •Diagnosis of moderate to severe vaginal atrophy at screening visit with VMI < 50% and vaginal pH > 4.5
- •At least one subjective symptom of vaginal atrophy (dryness, pain/burning sensation, pruritus, discharge, dyspareunia) related to a score of ≥ 65 on the visual analogue scale (VAS)
- •Indication for vaginal treatment with Gynoflor® (100 million viable L. acidophilus KS 400 and estriol 30 mcg per application) for 6 weeks because of symptomatic vaginal atrophy after menopause: 1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday).
- •Informed consent as documented by signature
排除标准
- •Administration of any form of oral/transdermal hormone therapy (HT) or selective estrogen receptor modulators (SERM) or phytoestrogens within 2 months prior to entry into or during the study.
- •Any use of over-the-counter vaginal products within 1 week prior to and during entry the study.
- •Known hypersensitivity or allergy to the investigational product
- •Estrogen dependent malignancy
- •Undiagnosed genital bleeding
- •Active thromboembolism
- •Active vulvovaginal Candidiasis, Trichomonas vaginitis or bacterial vaginitis based on light microscopy of vaginal secretions, vaginal pH, whiff test and KOH preparation
- •Active sexually transmitted infections (STI) including herpes simplex viral infection, gonorrhoea and Chlamydia.
- •Active urinary tract infection.
- •Pessary-users
- •Immunocompromised patients including those with human immunodeficiency viral infection, chronic glucocorticoid use or active treatment with immunosuppressive agents
- •Severe liver and/or kidney disease
- •Diabetes mellitus
- •Polyneuropathy
- •Skin disease affecting vulva or vagina, e.g. lichen sclerosus
- •Known or suspected non-compliance, drug or alcohol abuse
- •Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
- •Participation in another study with investigational drug within the 30 days preceding and during the present study.
结局指标
主要结局
Mean change in vaginal maturation index (VMI)
时间窗: 0 weeks, 4 weeks
次要结局
- Mean change in VMI(0 weeks,1 week, 2 weeks, 6 weeks)
- Mean change in vaginal pH(0 weeks,1 week, 2 weeks, 4 weeks, 6 weeks)
- Mean change in the most bothersome moderate and severe symptom of vaginal atrophy (MBS) . The symptoms include dryness, pain/burning sensation, pruritus, discharge, and dyspareunia.(0 weeks,1 week, 2 weeks, 4 weeks, 6 weeks)
- Number of lactobacilli(0 weeks,1 week, 2 weeks, 4 weeks, 6 weeks)
- Mean change in health-related quality of life (EQ-5D-5L). Mean change in Female Sexual Function Index (FSFI).(0 weeks,1 week, 2 weeks, 4 weeks, 6 weeks)
- Lactobacillary grade (LBG),(0 weeks,1 week, 2 weeks, 4 weeks, 6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Preventing Recurrent UTI With Vaginal EstrogenRecurrent Urinary Tract InfectionUrinary Tract InfectionsCystitis RecurrentNCT05551949Johns Hopkins University27
已完成
3 期
Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)Cardiovascular DiseasesCoronary DiseaseHeart DiseasesPostmenopauseMyocardial IschemiaNCT00000559National Heart, Lung, and Blood Institute (NHLBI)
进行中（未招募）
1 期
ocal Oestrogen Treatment in Postmenopausal Women Undergoing Pelvic Organ Prolapse Surgery (LOTUS)EUCTR2014-000179-18-GBniversity of Birmingham100
已完成
不适用
Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy TreatmentVaginal AtrophyNCT04717245University of Sao Paulo General Hospital75
终止
4 期
Postmenopausal Pessary Users: Estrogen Versus TrimosanVaginosisVaginosis, BacterialVaginal DischargeNCT03943823The University of Texas Health Science Center, Houston4